Agilent Technologies' Cancer Test Gets Expanded Approval From FDA

Dow Jones06-03

By Kelly Cloonan

Agilent Technologies got approval to expand the use of a cancer test to additional tumor types from the Food and Drug Administration.

The laboratory technologies company said Tuesday the FDA approved PD-L1 testing for use on the Dako Omnis platform, a technology used to diagnose diseases, to help identify patients with esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer and gastric or gastroesophageal junction who may be eligible for treatment with Keytruda.

The approval expands access to PD-L1 testing to four additional tumor types, adding to previous approvals for non-small cell lung cancer and head and neck squamous cell carcinoma. Those initial approved indications were only available on the Autostainer Link 48 platform and are now also approved for the Dako Omnis platform, allowing labs to consolidate testing across more tumor types within a single Dako Omnis workflow, the company said.

PD-L1 was developed by Agilent in partnership with Merck as a companion diagnostic for Merck's Keytruda.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

June 02, 2026 16:43 ET (20:43 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640925081?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 04:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640925081","market":"sg","top_or_hot":-1,"title":"Agilent Technologies' Cancer Test Gets Expanded Approval From FDA","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Agilent Technologies got approval to expand the use of a cancer test to additional tumor types from the Food and Drug Administration. \n</p>\n<p>\n  The laboratory technologies company said Tuesday the FDA approved PD-L1 testing for use on the Dako Omnis platform, a technology used to diagnose diseases, to help identify patients with esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer and gastric or gastroesophageal junction who may be eligible for treatment with Keytruda. \n</p>\n<p>\n  The approval expands access to PD-L1 testing to four additional tumor types, adding to previous approvals for non-small cell lung cancer and head and neck squamous cell carcinoma. Those initial approved indications were only available on the Autostainer Link 48 platform and are now also approved for the Dako Omnis platform, allowing labs to consolidate testing across more tumor types within a single Dako Omnis workflow, the company said. \n</p>\n<p>\n  PD-L1 was developed by Agilent in partnership with Merck as a companion diagnostic for Merck's Keytruda. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 02, 2026 16:43 ET (20:43 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agilent Technologies' Cancer Test Gets Expanded Approval From FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgilent Technologies' Cancer Test Gets Expanded Approval From FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-03 04:43</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Agilent Technologies got approval to expand the use of a cancer test to additional tumor types from the Food and Drug Administration. \n</p>\n<p>\n  The laboratory technologies company said Tuesday the FDA approved PD-L1 testing for use on the Dako Omnis platform, a technology used to diagnose diseases, to help identify patients with esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer and gastric or gastroesophageal junction who may be eligible for treatment with Keytruda. \n</p>\n<p>\n  The approval expands access to PD-L1 testing to four additional tumor types, adding to previous approvals for non-small cell lung cancer and head and neck squamous cell carcinoma. Those initial approved indications were only available on the Autostainer Link 48 platform and are now also approved for the Dako Omnis platform, allowing labs to consolidate testing across more tumor types within a single Dako Omnis workflow, the company said. \n</p>\n<p>\n  PD-L1 was developed by Agilent in partnership with Merck as a companion diagnostic for Merck's Keytruda. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 02, 2026 16:43 ET (20:43 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0238689110.USD","symbol_name":"贝莱德环球动力股票基金","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2640925081","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640925081","pubTimestamp":1780432980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Agilent Technologies got approval to expand the use of a cancer test to additional tumor types from the Food and Drug Administration.The laboratory technologies company said Tuesday the FDA approved PD-L1 testing for use on the Dako Omnis platform, a technology used to diagnose diseases, to help identify patients with esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer and gastric or gastroesophageal junction who may be eligible for treatment with Keytruda.The approval expands access to PD-L1 testing to four additional tumor types, adding to previous approvals for non-small cell lung cancer and head and neck squamous cell carcinoma. Those initial approved indications were only available on the Autostainer Link 48 platform and are now also approved for the Dako Omnis platform, allowing labs to consolidate testing across more tumor types within a single Dako Omnis workflow, the company said.PD-L1 was developed by Agilent in partnership with Merck as a compa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0238689110.USD":"贝莱德环球动力股票基金","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LABU":"三倍做多标普生物-Direxion","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","LU0234572021.USD":"高盛美国核心股票组合Acc","MRK":"默沙东","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU0058720904.USD":"联博国际健康护理基金A","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU2089279066.USD":"ALLIANZ GLOBAL WATER \"AT\" (USD) ACC","BK4534":"瑞士信贷持仓","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","LU1069347547.HKD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (HKD) INC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2229751404.USD":"ALLIANZ GLOBAL WATER \"AT3\" (USD) ACC","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","BK4559":"巴菲特持仓","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU2357627491.SGD":"TRP GLOBAL VALUE EQUITY \"AH\" (SGDHDG) ACC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","A":"安捷伦科技","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H"},"translate_title":"安捷伦科技的癌症测试获得FDA扩大批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"A":1.5,"LABU":1.5,"MRK":0.63},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Agilent Technologies got approval to expand the use of a cancer test to additional tumor types from the Food and Drug Administration. \n\n\n  The laboratory technologies company said Tuesday the FDA approved PD-L1 testing for use on the Dako Omnis platform, a technology used to diagnose diseases, to help identify patients with esophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer and gastric or gastroesophageal junction who may be eligible for treatment with Keytruda. \n\n\n  The approval expands access to PD-L1 testing to four additional tumor types, adding to previous approvals for non-small cell lung cancer and head and neck squamous cell carcinoma. Those initial approved indications were only available on the Autostainer Link 48 platform and are now also approved for the Dako Omnis platform, allowing labs to consolidate testing across more tumor types within a single Dako Omnis workflow, the company said. \n\n\n  PD-L1 was developed by Agilent in partnership with Merck as a companion diagnostic for Merck's Keytruda. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 02, 2026 16:43 ET (20:43 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640925081","isCrawlerRequest":true}